Kornimate/medical-research-clean huggingface dataset:
epidemiological studies and risk factor analysis of gerd in xiamen city

Conditions: Gastroesophageal Reflux Disease; Epidemiology; Risk Factors

Summary: gastroesophageal reflux disease (gerd) is a condition characterized by the reflux of gastric and duodenal contents into the esophagus, primarily manifested by symptoms such as acid regurgitation and heartburn. gerd significantly affects patients' daily lives and health-related quality of life. prolonged gastroesophageal reflux can lead to repeated irritation of the esophageal mucosa by gastric acid and acidic gastric contents, resulting in the replacement of normal squamous epithelium in the lower esophagus with metaplastic columnar epithelium. this pathological change, known as barrett's esophagus (be), is considered a precancerous lesion for esophageal adenocarcinoma.

gerd is a common gastrointestinal disorder with numerous risk factors that negatively impact patients' quality of life. abnormal psychological conditions may influence various aspects of gerd, including its onset, diagnosis, treatment, and prognosis. the incidence and risk factors of gerd vary in different countries or regions. currently, there is a lack of unified national epidemiological data on gerd in china. conducting epidemiological studies on gerd in china to identify risk factors and develop prevention and treatment measures tailored to the country's or specific regions' circumstances is crucial for reducing the incidence of gerd and improving patients' quality of life. in the context of the modern biomedical model of "biopsychosocial" health, actively researching the psychological conditions of patients, while also addressing their physical ailments and providing psychological treatment, emphasizes holistic care. this approach may comprehensively alleviate disease symptoms and enhance quality of life, potentially leading to new breakthroughs in the treatment of gerd. based on this, a specialized cohort for gastroesophageal reflux disease will be established, along with multicenter epidemiological and clinical research in the xiamen area. this initiative will help clarify the etiology of gerd and provide firsthand resources for evidence-based prevention and treatment.

Eligibility criteria:
inclusion criteria: * all patients had experienced typical reflux symptoms, i.e., mild heartburn and/or regurgitation symptoms, for at least 2 days per week or moderate/severe reflux symptoms for more than 1 day per week during the previous 3 months and had upper endoscopy examinations in the previous month. * cooperate with the questionnaire survey. * volunteer and sign the informed consent form. * permanent residents in xiamen. exclusion criteria: * malignant tumor. * partial or total gastrectomy. * failing to cooperate with the investigation because of the factors such as education level and language intelligence disorder, etc. * patients with severe heart, lung, kidney, liver, blood, nerve, endocrine and mental system diseases. * patients with mental retardation, etc.

Keywords: gastroesophageal reflux diseases barrett esophageal
safety and immunogenicity of vi-crm197 vaccine against s. typhi in adults, children, older infants and infants

Conditions: Typhoid Fever

Summary: this phase 2 trial is aimed to obtain information on the safety and immunogenicity of the vi-crm197 in subjects from various age groups in india and pakistan where typhoid fever is highly endemic and an efficacious vaccine against this disease is very much needed.


Eligibility criteria:
main eligibility criteria: * subjects belonging to 4 age groups will be enrolled into the trial: adults (18 to 45 years of age), children (24 to 59 months of age), older infants (9 to 12 months of age at enrollment) and infants (6 weeks of age at enrolment). * written informed consent will be obtained by the all subjects or their parents/ guardians (depending on the age group) before enrollment into the trial. * only females with a negative pregnancy test and willing to participate in family planning consultations (organized by the site study team) will be allowed to participate to the trial. * infants who have been vaccinated with 1 dose of bcg, hbv and opv at birth can be enrolled into the trial, while infants who have received dtwp+hbv+hib or opv due at 6 weeks of age as per local epi schedule cannot be enrolled into the trial.
thyroid hormone values and anti-thyroid peroxidase antibody positivity in recurrent pregnancy loss

Conditions: Autoimmune Thyroiditis; Recurrent Miscarriage

Summary: the aim of this study is to compare the thyroid hormone values and anti-thyroid peroxidase (anti-tpo) levels of women with a diagnosis of recurrent pregnancy loss (rpl) and healthy pregnancies. the primary objective is to find out the relationship between recurrent pregnancy loss with thyroid hormone levels and anti-tpo positivity.


Eligibility criteria:
inclusion criteria: * women with 2 or more pregnancy loses * for controls women with least one healthy baby exclusion criteria: * any other metabolic disease * women with one miscarriage

Keywords: thyroid hormones anti thyroid peroxidase antibody recurrent pregnancy loss
global patient registry of inherited retinal diseases

Conditions: Inherited Retinal Diseases

Summary: the purpose of this study is to better understand the natural history of inherited retinal disease (ird) and help inform patient management.


Eligibility criteria:
inclusion criteria: for participant selection: * participant has any clinically documented sign(s) and/or symptom(s) consistent with an inherited retinal disease (ird), or asymptomatic with documented retinal changes detected by imaging or electrophysiology * participant has documented genetic variant(s) (known pathogenic, likely pathogenic, or variants of uncertain significance) in relevant genes for any of the following irds: x-linked retinitis pigmentosa (xlrp) and/or achromatopsia (achm) * participant or legally acceptable representative has provided informed consent (and participant assent, when applicable) in accordance with local requirements * participant is able to have relevant visual and/or retinal assessments performed for caregiver selection: * caregiver has consent from the associated participant to participate in the study, or participant assent and consent from their legally acceptable representative * male or female aged greater than or equal to (\>=)18 years * identified by an enrolled participant (or their legally acceptable representative\*) as a primary caregiver * caregiver has provided informed consent in accordance with local requirements exclusion criteria: for participant selection: - participant has received a treatment in an ird-related interventional trial, or is being screened for an ird-related interventional trial for caregiver selection: - caregiver has an ird diagnosis and presents with symptoms (visual impairment)
levetiracetam treatment in adult subjects with parkinson's disease experiencing troublesome dyskinesias

Conditions: Idiopathic Parkinson Disease

Summary: this is a 41-week trial composed of two consecutive parts (part a, 14 weeks and optional part b, 27 weeks) to evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with idiopathic parkinson's disease, without negative impact on the benefit on the motor function of the antiparkinsonian treatment.


Eligibility criteria:
inclusion criteria: 1. male / female adult, 30 years old or more; 2. subject suffering from idiopathic parkinson's disease, diagnosed according to the uk brain bank criteria (see appendix 14.8) (1) , since a minimum of 3 years, and stabilized with regard to the motor function (ratio .on./.off. over the day); 3. subject treated with levodopa whether or not combined with any other antiparkinsonian drugs (except apomorphine) for minimum one year; 4. subject experiencing during .on. periods, despite several attempts of treatment adjustment, persistent troublesome dyskinesias: 1. with a minimum score of 2 on item 33 of the updrs-part iv (moderately disabling dyskinesias); 2. with a minimum score of 2 on item 32 of the updrs-part iv (dyskinesias present during more than 25% of the waking day). exclusion criteria: 1. dyskinesias that cannot reliably be characterized on a regular basis by the subject himself/herself (more than 5 .errors. on drc per 24 hours after repeated training); 2. subject currently treated with apomorphine or neuroleptic drugs either typical or atypical such as clozapine, olanzapine or risperidone; 3. subject currently treated with dopamine antagonists such as but not limited to metoclopramide, alizapride or phenothiazine derivatives (e.g. metopimazine). if necessary, the use of the dopamine antagonist domperidone is allowed. 4. subject who had undergone or who was scheduled for functional neurosurgery for parkinson's disease during the trial period;

Keywords: idiopathic parkinson's disease, levodopa induced dyskinesia, levetiracetam, keppra
treatment of hot flushes in breast cancer patients with acupuncture

Conditions: Breast Cancer; Postmenopause

Summary: in a randomized 3-group clinical study acupuncture is used for the relief of menopausal hot flushes and sleep disturbances in women treated for breastcancer. the three groups consists of 35 women given acupuncture once a week five times and 35 women given shamacupuncture once a week five times and 35 women with no kind of treatment. se-estradiol and endorphin is measured before and after the acupuncture. we want to state that acupuncture given five times once a week has a significant better effect on hot flushes and sleeping disturbances than shamacupuncture or no treatment at all. we also want to measure if there are any changes in se-estradiol and endorphine

breast cancer patients often have a higher prevalance of menopausal symptoms with hor flushes and sleeping disturbances than women in the general population, and hormone replacement therapy is not considered suitable for breast cancer patients because an increase in oestrogen is contraindicated. there has been some evidence that acupuncture is suitable treatment for hot flushes and therefore we had a small pilotproject where 25 women treated for breast cancer were given a course of classical body acupuncture with one 15 min treatment session per week for 5 weeks. the effekt was remarkable. we want to prove if this effekt is significantly better than shamacupuncture or to no treatment at all. this is a prospective, randomized and doubbleblinded study: 35 women get classical body acupuncture once a week 5 times 35 women get shamacupuncture once a week 5 times 35 women get no acupuncture. se-estradiol and se-endorphine will be measure before start of the first acupuncture and after the first and fifth acupuncture. the women with no treatment will have blodsamples too in the beginning and at the end of the fifth week.

Eligibility criteria:
inclusion criteria: * women older than 35 years treated for breastcancer having hot flushes and sleeping disturbances.it is not allowed to take estrogen as tablets or plaster. exclusion criteria: * failing to give consent * any use of estrogen as tablets or plaster

Keywords: breast cancer acupuncture post-menopausal hot flushes se-estradiol se-endorphine
the efficacy of galantamine treatment on attention in patients with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this study will examine whether the administration of galantamine is effective for improvement of attention and more effective for patients with serious disturbance of attention by administering galantamine to patients with alzheimer's dementia and performing an attention test on baseline, week 4 and 12.

this is an open label (all people know the identity of the intervention), multi-center, prospective study investigating the effect of galantamine on the attention of alzheimer's dementia patients. the objectives of this study include the evaluation of the relationship between change in attention after 4 weeks of galantamine administration and to investigate the effect of study drug after 12 weeks administration (the difference in the improvement of attention after the administration of galantamine). the secondary objective of this study is to clarify the causal relationship between improvement of attention and activities of daily living (adl). the design of this study is prospective, open-label, multi-center study. study populations are probable alzheimer's dementia patients diagnosed by nincds-adrda (national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association), dsm-iv (diagnostic and statistical manual of mental disorders) criteria. the efficacy of study drug will be assessed by evaluating cognitive function, attention and behavioral symptoms before and after the treatment using the following assessment tools: adas-k-cog11 (alzheimer's disease assessment scale - cognitive subscale), computerized attention test and activities of daily living. safety evaluations include adverse event monitoring and clinical lab tests. the patient is administered oral galantamine 8 mg/day for the first 4 weeks and then 16 mg/day. the dose of galantamine is increased up to 24 mg if tolerated.

Eligibility criteria:
inclusion criteria: * alzheimer's disease according to the criteria of dsm-iv, nincds-adrda * k-mmse (korean - mini mental state exam) is 10 to 24 * reliable guardian available to the patients * patient or guardian provided written informed consent before entering into the clinical trial exclusion criteria: * acetylcholine esterase inhibitors used to treat dementia taken within 30 days of the beginning in this clinical trial * neurodegenerative diseases (eg parkinson's disease, pick's disease, huntington's disease, down syndrome) * dementia related to head trauma and dementia related to brain damage due to cerebral hypoxia (hypoxic brain damage after cardiopulmonary resuscitation, hypoxic brain damage after surgery, hypoxic brain damage due to addiction, hypoxic brain damage due to shock) * brain tumor, nerve syphilis, meningitis, encephalitis * epilepsy

Keywords: alzheimer's disease galantamine dementia
comparison of dexamethasone alone vs in combination with pericardium 6 (p6) electrical stimulation or granisetron in the prevention of postoperative nausea and vomiting in patients undergoing breast cancer surgery

Conditions: Mammary Cancer; PONV

Summary: breast cancer is one of the three most common cancers worldwide, and the primary treatment method is surgery.since most patients are non-smokers who use opioids in the postoperative period, which are known risk factors for postoperative nausea and vomiting (ponv) according to the apfel risk score. breast surgery was identified as a strong risk factor for ponv. according to the previous studies, the incidence of ponv is 30-70% in patients undergoing the breast cancer surgery, which not only gives patients unpleasant and painful experience, but also prolongs the hospital stays and delay patient discharge and adds to hospital costs. we compared the effects of dexamethasone alone vs. in combination with pericardium 6 (p6) electrical stimulation or granisetron for inhibition of ponv in women undergoing breast cancer surgery.

186 patients who are planed to undergo elective breast cancer surgery under general anaesthesia into the following three groups: acupoint stimulation+dexamethasone (group acu, n=62), granisetron +dexamethasone (group gra, n=62), and dexamethasone alone (group dxm, n=62). the incidence of nausea, vomiting, and need for rescue antiemetics was recorded 2, 6, 24, and 48 h after surgery.

Eligibility criteria:
inclusion criteria: * women undergoing breast cancer resection under general anesthesia * aged between 18 to 65 * american society of anesthesiologists grade i-ii exclusion criteria: * using antiemetic drugs within 24 h before operation, * nausea or vomiting within 24 h before operation; * alcoholic or drug abuse, * abnormal liver and/or kidney function, diabetic or peripheral neuropathy patients, cardiovascular disease (excluding those with controlled hypertension). * refuse to participate clinical trial

Keywords: mammary cancer ponv electric stimulation therapy antiemetics
oral versus rectal ibuprofen for fever in young children - a randomized control study.

Conditions: Fever

Summary: fever is one of the most common symptoms in pediatrics and one of the most common reasons for visits in pediatricians' office and pediatric emergency departments. many parents consider fever to be the most terrifying symptom. ibuprofen is an effective and safe treatment for febrile children. until recently ibuprofen was available only in tablets suspension and as a liquid gel. all these dosage form are administered orally. rectal suppositories are often essential for treating febrile children who cannot take medications by mouth (e.g vomiting). in the current study we aim to compare the effect on fever of ibuprofen given as suspension with ibuprofen suppositories.


Eligibility criteria:
inclusion criteria: age: 3 mo- 4 years * weight 6 - 18 kg * rectal temperature \> 38.50 exclusion criteria: * treatment with acetaminophen in the last 4 hours * treatment with ibuprofen in the last 6 hours * unable to take oral or rectal medications * hypersensitivity to ibuprofen * renal failure * liver disease * rectal temperature can't be measured (due to anatomical or medical problem) * informed consent could not be granted

Keywords: ibuprofen suppository febrile children
study to evaluate the effect of six cycles of treatment with a combined oral contraceptive (ee 0.30 mg/drsp 3 mg) on quality of life.

Conditions: Healthy

Summary: the purpose of this study is to evaluate the effects on the quality of life and bmi of new contraceptives.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany.bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * female requiring contraceptives. * aged 18 to 35 if a non-smoker, aged 18 to 30 if a smoker. * regular menstrual cycle (defined as duration of 28 +/- 5 days). exclusion criteria: * no contraindication for oc use

Keywords: females requiring contraceptives
effect of high tone external muscle stimulation on peripheral arterial disease

Conditions: Diabetic Peripheral Neuropathy

Summary: to investigate the effect of high tone external muscle stimulation (htems) on endothelial dysfunction and walking parameters in peripheral vascular disease.

the patients will randomly be divided into two equal groups in number: 1. group a : thirty patients will participate in physical therapy program in form of high-tone external muscle stimulation (htems), with frequencies continuously will be scanned from 4096 hz to 31768 hz, allowing for a much higher power of up to 5000 mw to be introduced 3 times per week, for 10 weeks plus supervised regular aerobic exercise program on stationary bicycle with moderate intensity, ( score 12-14 on borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks . 2. group b: thirty patients will participate in a supervised regular aerobic exercise program only on stationary bicycle with moderate intensity, (score 12-14 on borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks.

Eligibility criteria:
inclusion criteria: * 1- both genders are allowed to participate in the study. 2- the age range of patients will be from 50-60 years 3- all patients are diabetic from 5-7 years. 4- abpi for all patients will be ranged from 0.65 to 0. 9 5- all patients are medically and psychologically stable. 6- only ambulant patient without any aids will be selected 7- all patients are non smokers. exclusion criteria: 1. patients with abpi ( ankle brachial pressure index ≤ 0.4 ) 2. patients who are unable to walk on treadmill or unable to attend sessions at the physical therapy department at cairo university hospitals, 3 times a week. 3. patients with unstable cardiovascular conditions (those with a known history of recent myocardial infarction, uncontrolled hypertension, ischemic attacks, stroke, and congestive heart failure) will be excluded from this study. 4. patients with neurological problems that cause leg pain and polyneuropathy. 5. patients with active malignancy will be excluded from study 6. patients with ischemic ulcers or gangrenes 7. patients with a vascular surgical procedure or angioplasty within the previous year will be excluded from the study 8. patients with musculoskeletal disorders (diagnosed with severe osteoporosis, severe osteoarthritis or joint replacement). -
mk-0954e phase iii long-term study in participants with hypertension (mk-0954e-356)

Conditions: Hypertension

Summary: this study has two parts. in the first part, the efficacy and safety mk-0954e (losartan potassium 50 mg \[l50\] (+) hydrochlorothiazide 12.5 mg \[h12.5\] (+) amlodipine besylate 5mg \[a5\]) will be evaluated and compared to the efficacy and safety of mk-0954h (l50/h12.5) in japanese participants. in the second part, the safety and tolerability of long-term use of open-label mk-0954e in participants with hypertension will be evaluated. the primary hypothesis is that mk-0954e is more effective in lowering mean trough sitting diastolic blood pressure (sidbp) after 8 weeks of treatment compared to mk-954h (l50/h12.5 mg) in japanese participants with essential hypertension who are not adequately controlled following a 8-week treatment with filter period study drug of mk-954h.


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of essential hypertension * participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication * participant has a mean trough sidbp of ≥ 90 mmhg and \< 110 mmhg * participant has a mean trough sisbp of ≥ 140 mmhg and \< 200 mmhg * participant has no clinically significant abnormality at screening visit exclusion criteria: * participant is currently taking \>2 antihypertensive medications * participant has a history of significant multiple and/or severe allergies to ingredients of nu-lotan or preminent, amlodipine or dihydropyridine drug and thiazide drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines) * participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence * participant is pregnant or breastfeeding, or expecting to conceive or the pregnancy test is positive at screening visit (visit 1) * participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent

Keywords: essential hypertension antihypertensive agents blood pressure uncontrolled hypertension